IN8bio, Inc.
INAB
$1.10
-$0.08-6.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.34M | 9.62M | 9.65M | 9.90M | 10.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.20M | 19.47M | 19.86M | 21.05M | 23.13M |
| Operating Income | -19.20M | -19.47M | -19.86M | -21.05M | -23.13M |
| Income Before Tax | -18.67M | -18.98M | -19.44M | -20.66M | -23.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.67 | -18.98 | -19.44 | -20.66 | -23.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.67M | -18.98M | -19.44M | -20.66M | -23.89M |
| EBIT | -19.20M | -19.47M | -19.86M | -21.05M | -23.13M |
| EBITDA | -17.80M | -17.84M | -18.09M | -19.16M | -21.12M |
| EPS Basic | -2.05 | -3.04 | -4.94 | -6.62 | -10.26 |
| Normalized Basic EPS | -1.28 | -1.90 | -3.09 | -4.13 | -5.99 |
| EPS Diluted | -2.05 | -3.04 | -4.94 | -6.62 | -10.26 |
| Normalized Diluted EPS | -1.28 | -1.90 | -3.09 | -4.13 | -5.99 |
| Average Basic Shares Outstanding | 50.57M | 35.23M | 18.33M | 13.83M | 10.87M |
| Average Diluted Shares Outstanding | 50.57M | 35.23M | 18.33M | 13.83M | 10.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |